A HGF/cMET autocrine loop is operative in multiple myeloma bone marrow endothelial cells and may represent a novel therapeutic target

Clinical Cancer Research

Volumn 20, Issue 22, 2014, Pages 5796-5807

  Ferrucci, Arianna ^a   Moschetta, Michele ^a   Frassanito, Maria Antonia ^a   Berardi, Simona ^a   Catacchio, Ivana ^a   Ria, Roberto ^a   Racanelli, Vito ^a   Caivano, Antonella ^b   Solimando, Antonio Giovanni ^a   Vergara, Daniele ^c   Maffia, Michele ^c   Latorre, Dominga ^c   Rizzello, Antonia ^c   Zito, Alfredo ^d   Ditonno, Paolo ^d   Maiorano, Eugenio ^a   Ribatti, Domenico ^a   Vacca, Angelo ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^c UNIVERSITY OF SALENTO   (Italy)

^d DI VENERE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; LENALIDOMIDE; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; NEUTRALIZING ANTIBODY; RNA; SCATTER FACTOR; TYROSINE KINASE RECEPTOR; TYROSINE KINASE RECEPTOR MESENCHYMAL EPITHELIAL TRANSITION FACTOR; UNCLASSIFIED DRUG; ((3Z)-N-(3-CHLOROPHENYL)-3-((3,5-DIMETHYL-4-((4-METHYLPIPERAZIN-1-YL)CARBONYL)-1H-PYRROL-2-YL)METHYLENE)-N-METHYL-2-OXO-2,3-DIHYDRO-1H-INDOLE-5-SULFONAMIDE); ANGIOGENESIS INHIBITOR; CYTOKINE; INDOLE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEOME; SCATTER FACTOR RECEPTOR; SULFONAMIDE;

ADULT; AGED; ANEMIA; ANTIANGIOGENIC ACTIVITY; ARTICLE; BONE MARROW CELL; CELL ACTIVITY; CELL ADHESION; CELL MOTILITY; CELL SPREADING; CHEMOTAXIS; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REGULATORY MECHANISM; RELAPSE; SIGNAL TRANSDUCTION; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; AUTOCRINE EFFECT; BIOSYNTHESIS; CELL MOTION; GENE EXPRESSION; GENETICS; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; PROTEOMICS;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; AUTOCRINE COMMUNICATION; BONE MARROW CELLS; CELL MOVEMENT; CYTOKINES; ENDOTHELIAL CELLS; FEMALE; GENE EXPRESSION; HEPATOCYTE GROWTH FACTOR; HUMANS; INDOLES; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; PIPERAZINES; PROTEOME; PROTEOMICS; PROTO-ONCOGENE PROTEINS C-MET; SULFONAMIDES;

EID: 84918533839     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0847     Document Type: Article

References (48)

1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011;364:1046-60.
2. Vacca A, Ribatti D, Roncali L, Ranieri G, Serio G, Silvestris F, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994;87:503-8.
3. Rajkumar SV, Mesa RA, Fonseca R, Schroeder G, Plevak MF, Dispenzieri A, et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 2002;8:2210-6.
4. Munshi NC, Wilson C. Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis. Semin Oncol 2001;28:565-9.
5. Podar K, Tai YT, Hideshima T, Vallet S, Richardson PG, Anderson KC. Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs 2009;14:99-127.
6. Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L, et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 1992;119:629-41.
7. Zhang YW, Su Y, Volpert OV, Vande Woude GF. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc Natl Acad Sci U S A 2003;100:12718-23.
8. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-25.
9. Børset M, Lien E, Espevik T, Helseth E, Waage A, Sundan A. Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-MET in human myeloma cell lines. J Biol Chem 1996;271:24655-61.
10. Moschetta M, Basile A, Ferrucci A, Frassanito MA, Rao L, Ria R, et al. Novel targeting of phospho-cMET overcomes drug resistance and induces anti-tumor activity in multiple myeloma. Clin Cancer Res 2013;19:4371-82.
11. Takai K, Hara J, Matsumoto K, Hosoi G, Osugi Y, Tawa A, et al. Hepatocyte growth factor is constitutively produced by human bone marrow stromal cells and indirectly promotes hematopoiesis. Blood 1997;89:1560-5.
12. Seidel C, Børset M, Turesson I, Abildgaard N, Sundan A, Waage A. Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. Blood 1998;91:806-12.
13. Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, et al. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 2005;65:1479-88.
14. Koon EC, Ma PC, Salgia R, Welch WR, Christensen JG, Berkowitz RS, et al. Effect of a c-Met-specific, ATP-competitive small-molecule inhibitor SU11274 on human ovarian carcinoma cell growth, motility, and invasion. Int J Gynecol Cancer 2008;18:976-84.
15. International Myeloma Working Group. Criteria for the classification of monoclonalgammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749-57.
16. Vacca A, Ria R, Semeraro F, Merchionne F, Coluccia M, Boccarelli A, et al. Endothelial cells in the bone marrow of patients with multiple myeloma. Blood 2003;102:3340-8.
17. De Luisi A, Ferrucci A, Coluccia AML, Ria R, Moschetta M, De Luca E, et al. Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma. Clin Cancer Res 2011;17:1935-46.
18. Berardi S, Caivano A, Ria R, Nico B, Savino R, Terracciano R, et al. Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targets. Oncogene 2012;31:2258-69.
19. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)). Methods 2001;25:402-8.
20. Roccaro AM, Hideshima T, Raje N, Kumar S, Ishitsuka K, Yasui H, et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 2006;66:184-91.
21. Ria R, Catacchio I, Berardi S, De Luisi A, Caivano A, Piccoli C, et al. HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target. Clin Cancer Res 2014;20:847-58.
22. Vergara D, Chiriacò F, Acierno R, Maffia M. Proteomic map of peripheral blood mononuclear cells. Proteomics 2008;8:2045-51.
23. Ribatti D, Nico B, Vacca A, Presta M. The gelatin sponge-chorioallantoic membrane assay. Nat Protoc 2006;1:85-91.
24. Re RN, Cook JL. An intracrine view of angiogenesis. BioEssays 2006;28:943-53.
25. Purdue MP, Lan Q, Menashe I, Zheng T, Zhang Y, Yeager M, et al. Variation in innate immunity genes and risk of multiple myeloma. Hematol Oncol 2011;29:42-6.
26. Nakayama T, Hieshima K, Izawa D, Tatsumi Y, Kanamaru A, Yoshie O. Cutting edge: profile of chemokine receptor expression on human plasma cells accounts for their efficient recruitment to target tissues. J Immunol 2003;170:1136-40.
27. Aggarwal R, Ghobrial IM, Roodman GD. Chemokines in multiple myeloma. Exp Hematol 2006;34:1289-95.
28. Chen L, Zhang SS, Barnstable CJ, Tombran-Tink J. PEDF induces apoptosis in human endothelial cells by activating p38 MAP kinase dependent cleavage of multiple caspases. Biochem Biophys Res Commun 2006;348:1288-95.
29. Ribatti D, Basile A, Ruggieri S, Vacca A. Bone marrow vascular niche and the control of angiogenesis in multiple myeloma. Front Biosci 2014;19:304-11.
30. Ria R, Vacca A, Russo F, Cirulli T, Massaia M, Tosi P, et al. A VEGF-dependent autocrine loop mediates proliferation and capillarogenesis in bone marrow endothelial cells of patients with multiple myeloma. Thromb Haemost 2004;92:1438-45.
31. Cesca M, Bizzaro F, Zucchetti M, Giavazzi R. Tumor delivery of chemotherapy combined with inhibitors of angiogenesis and vascular targeting agents. Front Oncol 2013;3:259.
32. Lopuch S, Kawalec P, Wis̈niewska N. Effectiveness of targeted therapy as monotherapy or combined therapy in patients with relapsed or refractory multiple myeloma: a systematic review and meta-analysis. Hematology 2014 Feb 28. [Epub ahead of print].
33. Corso S, Comoglio PM, Giordano S. Cancer therapy: can the challenge be MET? Trends Mol Med 2005;11:284-92.
34. Ding S, Merkulova-Rainon T, Han ZC, Tobelem G. HGF receptor upregulation contributes to the angiogenic phenotype of human endothelial cells and promotes angiogenesis in vitro. Blood 2003;101:4816-22.
35. Liu Y, Wilkinson FL, Kirton JP, Jeziorska M, Iizasa H, Sai Y, et al. Hepatocyte growth factor and c-Met expression in pericytes: implications for atherosclerotic plaque development. J Pathol 2007;212:12-9.
36. Mahtouk K, Tjin EP, Spaargaren M, Pals ST. The HGF/MET pathway as target for the treatment of multiple myeloma and B-cell lymphomas. Biochim Biophys Acta 2010;1806:208-19.
37. Xin X, Yang S, Ingle G, Zlot C, Rangell L, Kowalski J, et al. Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Am J Pathol 2001;158:1111-20.
38. Vincent L, Jin DK, Karajannis MA, Shido K, Hooper AT, Rashbaum WK, et al. Fetal stromal-dependent paracrine and intracrine vascular endothelial growth factor-A/vascular endothelial growth factor receptor-1 signaling promotes proliferation and motility of human primary myeloma cells. Cancer Res 2005;65:3185-92.
39. Rocci A, Gambella M, Aschero S, Baldi I, Trusolino L, Cavallo F, et al. MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients. Br J Haematol 2014;164:841-50.
40. Yap TA, Olmos D, Brunetto AT, Tunariu N, Barriuso J, Riisnaes R, et al. Phase I trial of a selective cMET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol 2011;29:1271-9.
41. Spigel DR, Ervin TJ, Ramlau R, Daniel DB, Goldschmidt JH, Blumenschein GR, et al. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. J Clin Oncol 29: 2011 (suppl; abstr 7505).
42. Ria R, Todoerti K, Berardi S, Coluccia AML, De Luisi A, Mattioli M, et al. Gene expression pro filing of bone marrow endothelial cells in patients with multiple myeloma. Clin Cancer Res 2009;15:5369-78.
43. Bao H, Jiang M, Zhu M, Sheng F, Ruan J, Ruan C. Overexpression of Annexin II affects the proliferation, apoptosis, invasion and production of proangiogenic factors in multiple myeloma. Int J Hematol 2009;90:177-85.
44. Mogami T, Yokota N, Asai-Sato M, Yamada R, Koizume S, Sakuma Y, et al. Annexin A4 is involved in proliferation, chemo-resistance and migration and invasion in ovarian clear cell adenocarcinoma cells. PLoS ONE 2013;8:e80359.
45. Kalinina EV, Berezov TT, Shtil' AA, Chernov NN, Glazunova VA, Novichkova MD, et al. Expression of peroxiredoxin 1, 2, 3, and 6 genes in cancer cells during drug resistance formation. Bull Exp Biol Med 2012;153:878-81.
46. Guo S, Zou J, Wang G. Advances in the proteomic discovery of novel therapeutic targets in cancer. Drug Des Devel Ther 2013;7:1259-71.
47. Demarchi F, Schneider C. The calpain system as a modulator of stress/damage response. Cell Cycle 2007;6:136-8.
48. Gherardi E, Birchmeier W, Birchmeier C, Woude GV. Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012;12:89-103.